

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Thomas J.F. Nieland, Monty Krieger and Thomas Kirchhausen

Serial No.: 10/381,746 Art Unit: Not Yet Assigned

Filed: October 8, 2003 Examiner: Not Yet Assigned

For: **COMPOUNDS FOR MODULATION OF CHOLESTEROL TRANSPORT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including (5) pages of Form PTO-1449 and copies of forty-seven (47) documents cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

**U.S. Patents**

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
3,625,214	12-07-1971	Higuchi et al.	128/260
4,789,734	12-06-1988	Pierschbacher	530/395
4,906,474	03-06-1990	Langer et al.	424/428
4,925,673	05-15-1990	Steiner et al.	424/455
5,925,333	07-20-1999	Krieger et al.	424/9.1

U.S.S.N.: 10/681,746

Filed: October 8, 2003

INFORMATION DISCLOSURE STATEMENT

5,962,322	10-05-1999	Kozarsky et al.	435/375
6,121,319	09-19-2000	Sommers	514/548
6,350,859	02-26-2002	Krieger et al.	530/388.22
6,429,289	08-06-2002	Krieger et al.	530/350

**Foreign Documents**

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 96/00288	01-04-1996	Massachusetts Inst. Technology	PCT
WO 99/11288	03-11-1999	Massachusetts Inst. Technology	PCT

**Publications**

ACTON, et al., "Expression cloning of SR-BI, a CD36-related class B scavenger receptor," *J. Biol. Chem.* 269:21003-21009 (1994).

ACTON, et al., "Identification of Scavenger receptors SR-B1 as a high density lipoprotein receptor," *Science* 271:518-520 (1996).

ARAI, et al., "Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene," *J. Biol. Chem.* 274:2366-2371 (1999).

BALDINI, et al., "Cloning of a Rab3 Isotype Predominately Expressed in Adipocytes", *Proc. Natl. Acad. Sci. U.S.A.* 89: 5049-5052 (1992).

BRAUN, et al., "Loss of SR-BI expression leads to early onset of occlusive atherosclerosis coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice," *Cir. Res.* 90: 270- 276 (2002).

BROWN & GOLDSTEIN, "A receptor-mediated pathway for cholesterol homeostasis," *Science* 232: 34-47 (1986).

CHARRON, et al., "A Glucose Transport Protein Expressed Predominately in Insulin-responsive Tissues," *Proc. Natl. Acad. Sci. USA* 86: 2535-2539 (1989).

FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," *Proc. Natl. Acad. Sci. USA* 88:4931-4935 (1991).

U.S.S.N.: 10/681,746

Filed: October 8, 2003

INFORMATION DISCLOSURE STATEMENT

GLASS, et al., "Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad," *Proc. Natl. Acad. Sci. USA* 80:5435-5439 (1983).

GLASS, et al., "Uptake of high-density lipoprotein-associated apo-protein A-I and cholesterol esters by 16 tissues of the rat *in vivo* and by adrenal cells and hepatocytes *in vitro*," *J. Biol. Chem.* 260:744-750 (1985).

GREGORIADIS, "Liposomes" in Drug Carriers in Biology and Medicine Chapter 14 pp. 287-341 (Academic Press, 1979).

GU, et al., "Scavenger receptor class B, type I-mediated [<sup>3</sup>H] cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor," *J. Biol. Chem.* 275: 29993-30001 (2000).

GU, et al., "The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain," *J. Biol. Chem.* 273:26338-26348 (1998).

HOLM, et al., "Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI," *Blood* 99: 1817-1824 (2002).

HUNT & CALDERWOOD, "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines", *Gene* 87: 199-204 (1990).

INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neural and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages," *J. Clin. Invest.* 92(2):750-757 (1993). JI, et al., "Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux," *J. Biol. Chem.* 272:20982-20985 (1997).

JIAN, et al., "Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors," *J. Biol. Chem.* 273: 5599-5606 (1998).

KAPOOR, et al., "Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5," *J. Cell Biol.* 150: 975-988 (2000).

KINGSLEY, et al., "Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," *Proc. Natl. Acad. Sci. USA* 81:5454-5458 (1984).

KOZARSKY, et al., "Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels," *Nature* 387:414-417 (1997).

U.S.S.N.: 10/681,746

Filed: October 8, 2003

INFORMATION DISCLOSURE STATEMENT

KOZARSKY, et al., "Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse," *Arterio. Thromb. Vasc. Biol.* 20: 721-727 (2000).

KRIEGER, "Complementation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants", *Cell* 33: 413-422 (1983).

KRIEGER, "Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein reception SR-BI," *Ann. Rev. Biochem.* 68:523-558 (1999).

KRIEGER, "Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems," *J. Clin. Invest.* 108: 793-797 (2001).

LENCER, et al., "Membrane traffic and the cellular uptake of cholera toxin," *Biochim. Biophys. Acta* 1450: 177-190 (1999).

MARDONES, et al., "Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice," *J. Lipid Res.* 42: 170-180 (2001).

MIETTINEN, et al., "Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice," *J Clinical Invest.* 108: 1717-1722 (2001).

PITAS, et al., "Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy," *Arteriosclerosis* 1: 177 (1981).

RIGOTTI, et al., Regulation by adrenocortotropic hormone of the in vitro expression of scavenger receptor class B Type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland," *J. Biol. Chem.* 271:33545-33549 (1996).

SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageenane Granuloma Foam Cell Formation in Watanabe Heritable Hyperlipidemic Rabbits," *Arterioscler. Thromb.* 14(1):70-76 (1994).

SPIRO, et al., "Wortmannin alters the transferrin receptor endocytic pathway in vivo and in vitro," *Mol. Biol. Cell.* 7: 355-367 (1996).

STEIN, et al., "Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether," *Biochim. Biophys. Acta*, 752: 98 (1983).

TEMEL, et al., "Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake," *J. Biol. Chem.* 277(29): 26565-26572 (2002).

U.S.S.N.: 10/681,746

Filed: October 8, 2003

INFORMATION DISCLOSURE STATEMENT

TRIGATTI, et al., "Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology," *Proc. Nat. Acad. Sci. USA* 96: 9322-9327 (1999).


UEDA, et al., "Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics," *J. Biol. Chem.* 275: 20368-20373 (2000).

UITTENBOGAARD, et al., "Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex," *J. Biol. Chem.* 277: 4925-4931 (2002).

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Dated: December 31, 2003

HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8473  
FAX 404-817-8588  
[www.hklaw.com](http://www.hklaw.com)

U.S.S.N.: 10/681,746  
Filed: October 8, 2003  
INFORMATION DISCLOSURE STATEMENT

**Certificate of Mailing under 37 C.F.R. § 1.8(a)**

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 31, 2003



Jennifer Vicente

# 1485297\_v1

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/681,746
(use as many sheets as necessary)		Filing Date	October 8, 2003
		First Named Inventor	Thomas J.F. Nieland
		Group Art Unit	
		Examiner Name	
Sheet	1	of	5
		Attorney Docket Number	MIT 9952

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**Examine  
Signature** \_\_\_\_\_ **Date  
Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/681,746
(use as many sheets as necessary)		Filing Date	October 8, 2003
		First Named Inventor	Thomas J.F. Nieland
		Group Art Unit	
		Examiner Name	
Sheet	2	of	5
		Attorney Docket Number	MIT 9952

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ACTON, et al., "Expression cloning of SR-BI, a CD36-related class B scavenger receptor," <i>J. Biol. Chem.</i> 269:21003-21009 (1994).	
		ACTON, et al., "Identification of Scavenger receptors SR-B1 as a high density lipoprotein receptor," <i>Science</i> 271:518-520 (1996).	
		ARAI, et al., "Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene," <i>J. Biol. Chem.</i> 274:2366-2371 (1999).	
		BALDINI, et al., "Cloning of a Rab3 Isotype Predominately Expressed in Adipocytes", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89: 5049-5052 (1992).	
		BRAUN, et al., "Loss of SR-BI expression leads to early onset of occlusive atherosclerosis coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice," <i>Cir. Res.</i> 90: 270- 276 (2002).	
		BROWN & GOLDSTEIN, "A receptor-mediated pathway for cholesterol homeostasis," <i>Science</i> 232: 34-47 (1986).	
		CHARRON, et al., "A Glucose Transport Protein Expressed Predominately in Insulin-responsive Tissues," <i>Proc. Natl. Acad. Sci. USA</i> 86: 2535-2539 (1989).	
		FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 88:4931-4935 (1991).	
		GLASS, et al., "Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad," <i>Proc. Natl. Acad. Sci. USA</i> 80:5435-5439 (1983).	
		GLASS, et al., "Uptake of high-density lipoprotein-associated apo-protein A-I and cholesterol esters by 16 tissues of the rat <i>in vivo</i> and by adrenal cells and hepatocytes <i>in vitro</i> ," <i>J. Biol. Chem.</i> 260:744-750 (1985).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/681,746
Filing Date	October 8, 2003		
First Named Inventor	Thomas J.F. Nieland		
Group Art Unit			
Examiner Name			
Sheet      3      of      5	Attorney Docket Number	MIT 9952	

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GREGORIADIS, "Liposomes" in <u>Drug Carriers in Biology and Medicine</u> Chapter 14 pp. 287-341 (Academic Press, 1979).	
		GU, et al., "Scavenger receptor class B, type I-mediated [ <sup>3</sup> H] cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor," <i>J. Biol. Chem.</i> 275: 29993-30001 (2000).	
		GU, et al., "The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain," <i>J. Biol. Chem.</i> 273:26338-26348 (1998).	
		HOLM, et al., "Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI," <i>Blood</i> 99: 1817-1824 (2002).	
		HUNT & CALDERWOOD, "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines", <i>Gene</i> 87: 199-204 (1990).	
		INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neural and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages." <i>J. Clin. Invest.</i> 92(2):750-757 (1993).JI, et al., "Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux," <i>J. Biol. Chem.</i> 272:20982-20985 (1997).	
		JIAN, et al., "Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors," <i>J. Biol. Chem.</i> 273: 5599-5606 (1998).	
		KAPOOR, et al., "Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5," <i>J. Cell Biol.</i> 150: 975-988 (2000).	
		KINGSLEY, et al., "Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," <i>Proc. Natl. Acad. Sci. USA</i> 81:5454-5458 (1984).	
		KOZARSKY, et al., "Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels," <i>Nature</i> 387:414-417 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
(use as many sheets as necessary)					
Sheet	4	of	5	Application Number	10/681,746
				Filing Date	October 8, 2003
				First Named Inventor	Thomas J.F. Nieland
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MIT 9952

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		KOZARSKY, et al., "Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse," <i>Arterio. Thromb. Vasc. Biol.</i> 20: 721-727 (2000).
		KRIEGER, "Complementation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants", <i>Cell</i> 33: 413-422 (1983).
		KRIEGER, "Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein reception SR-BI," <i>Ann. Rev. Biochem.</i> 68:523-558 (1999).
		KRIEGER, "Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems," <i>J. Clin. Invest.</i> 108: 793-797 (2001).
		LENCER, et al., "Membrane traffic and the cellular uptake of cholera toxin," <i>Biochim. Biophys. Acta</i> 1450: 177-190 (1999).
		MARDONES, et al., "Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice," <i>J. Lipid Res.</i> 42: 170-180 (2001).
		MIETTINEN, et al., "Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice," <i>J Clinical Invest.</i> 108: 1717-1722 (2001).
		PITAS, et al., "Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy," <i>Arteriosclerosis</i> 1: 177 (1981).
		RIGOTTI, et al., Regulation by adrenocortotropic hormone of the in vitro expression of scavenger receptor class B Type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland," <i>J. Biol. Chem.</i> 271:33545-33549 (1996).
		SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageeene Granuloma Foam Cell Formation in Watanabe Heritable Hyperlipidemic Rabbits," <i>Arterioscler. Thromb.</i> 14(1):70-76 (1994).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			
Sheet	5	of	5
		Attorney Docket Number	
MIT 9952			

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials <sup>a</sup>	Cite No. <sup>b</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>c</sup>
		SPIRO, et al., "Wortmannin alters the transferrin receptor endocytic pathway in vivo and in vitro," <i>Mol. Biol. Cell.</i> 7: 355-367 (1996).	
		STEIN, et al., "Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether," <i>Biochim. Biophys. Acta</i> , 752: 98 (1983).	
		TEMEL, et al., "Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake," <i>J. Biol. Chem.</i> 277(29): 26565-26572 (2002).	
		TRIGATTI, et al., "Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology," <i>Proc. Nat. Acad. Sci. USA</i> 96: 9322-9327 (1999).	
		UEDA, et al., "Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics," <i>J. Biol. Chem.</i> 275: 20368-20373 (2000).	
		UITTENBOGAARD, et al., "Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex," <i>J. Biol. Chem.</i> 277: 4925-4931 (2002).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>a</sup> Unique citation designation number <sup>b</sup> See attached Kinds of U.S. Patent Documents. <sup>c</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>d</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>e</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>f</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

